>>BRISBANE, Calif., Oct. 22 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN - News) announced today relevant presentations that will be discussed in multiple scientific sessions at the 54th Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, MA from October 24-28, 2003. Among the relevant presentations taking place are the following:
Saturday, October 25, 2003
Poster 292: 5:30 p.m. - 8:00 p.m.
Synergistic Effects of Type 1 (Infergen(R)) and Type
2 (Actimmune(R)) Interferons in Preclinical Models of
HCV: Demonstration of Potential Efficacy
Poster 304: 5:30 p.m. - 8:00 p.m.
Daily Dosing Regimen of Consensus Interferon and
Ribavirin for Treatment-Naive Patients with Chronic
Hepatitis C and Genotype 1
Poster 308: 5:30 p.m. - 8:00 p.m.
Delivery of Consensus Interferon by Continuous
Infusion for the Treatment of Chronic Hepatitis C: A
Pilot Viral Kinetic Study in Nonresponder Patients
Poster 314: 5:30 p.m. - 8:00 p.m.
A Pilot Study of a Novel Anti-Inflammatory and Anti-
Fibrotic Agent, Pirfenidone, in Patients with Liver
Cirrhosis
Sunday, October 26, 2003
Poster 697: 8:00 a.m. - 5:00 p.m.
Preclinical Activity of Pirfenidone (5-Methyl-
1Phenyl-2(IH)-Pyridone) in Cell-Based Models of
Nonalcoholic Steatohepatitis
Tuesday, October 28, 2003
Oral
presentation: 11:30 a.m. - 11:45 a.m.
Retreatment of Standard Interferon/Ribavirin
Nonresponder Patients with Chronic Hepatitis C with
Daily Consensus Interferon and Ribavirin Yields High
Sustained Response Rates
InterMune will also be hosting a satellite symposium entitled "Management of HCV Infection in Patients Who Are Nonresponders to Previous Therapy," starting at 6:30 p.m. on Sunday, October 26th, in the Constitution Ballroom, Sheraton Boston Hotel, Boston, MA. The program will include presentations by several leading physicians with the aim of informing participants of emerging treatment options for HCV patients who are nonresponders to previous therapy.
About Infergen® (interferon alfacon-1)
Infergen® is a bio-optimized type 1 interferon alpha indicated for treatment of adult patients with chronic HCV infections. Infergen® is the only interferon alpha with data in the label regarding use in patients following relapse or non-response to treatment with certain previous treatments. The most common side effects are flu-like symptoms (i.e. headache, fatigue, fever, myalgia, and rigors). Physicians and patients can obtain additional prescribing information regarding Infergen®, including the product's safety profile, by visiting www.infergen.com, including the black box warning for all interferon alphas regarding psychiatric, autoimmune, ischemic and infectious disorders.<<
snip
Cheers, Tuck |
